Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | S100A4 | P26447 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40706 | 1.00 | ALDH1A1 (0.62) | ALDH1A1HIF1AVCAM1AKR1C2AKR1C1 | |
| SCHEMBL6619 | 0.83 | TDP1 (0.64) | ALDH1A1HIF1AVCAM1AKR1C2AKR1C1 | |
| SCHEMBL29399835 | 0.83 | TDP1 (0.64) | ALDH1A1HIF1AVCAM1AKR1C2AKR1C1 | |
| SCHEMBL28871017 | 0.81 | TDP1 (0.50) | ALDH1A1HIF1AVCAM1AKR1C2AKR1C1 | |
| SCHEMBL1561802 | 0.80 | TSHR (0.56) | ALDH1A1S100A4TRPV1ATMTDP1 | |
| Ethylene SCHEMBL27608389 | 0.80 | TDP1 (0.60) | ALDH1A1HIF1AVCAM1AKR1C2AKR1C1 | |
| SCHEMBL12577116 | 0.79 | ALDH1A1 (0.38) | ALDH1A1HIF1AVCAM1AKR1C2AKR1C1 | |
| SCHEMBL204357 | 0.78 | S100A4 (0.61) | ALDH1A1S100A4TRPV1MAPTMAPK1 | |
| SCHEMBL29395434 | 0.78 | S100A4 (0.56) | ALDH1A1S100A4TRPV1MAPTLMNA | |
| SCHEMBL11579276 | 0.78 | ALDH1A1 (0.67) | ALDH1A1HIF1AVCAM1ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12453731-B2 | Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-10-28 | — | — | US | disclosed |
| WO-2025136671-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025108411-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京沐华生物科技有限责任公司 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096856-A1 | COVALENT CEREBLON LIGANDS | C4 THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096710-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4540230-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023007188-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
| EP-4110765-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | Board of Regents, The University of Texas System (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4076459-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022189387-A1 | TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022108984-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MACROCYCLIC MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220152027-A1 | ANILINE-BASED WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2022-05-19 | — | — | US | disclosed |
| WO-2022081758-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3976189-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | Galapagos N.V. (BE) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022067063-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453731-B2 | Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof | MLLT1, WDR77, MLLT3 | ALDH1A1 2270/4885HIF1A 2343/4885VCAM1 2264/4885 |
| US-20220152027-A1 | ANILINE-BASED WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | MLLT1, WDR77, MLLT3 | ALDH1A1 2270/4885HIF1A 2343/4885VCAM1 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.